ArticleAnnals of clinical microbiology and antimicrobials2025
Biocide, antifungal susceptibility and virulence characteristics of Clade 1 Candidozyma auris strains.
Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Adaptive susceptibility shifts in Candidozyma auris following biocidal exposure: Exploratory effects on antifungal and biocidal susceptibility.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Clinical and Microbiological Characteristics of EarlyAntibiotics (Basel, Switzerland) · 2026Article
- Biocide Response of Candida auris.Mycoses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundCandidozyma auris is an emerging multidrug-resistant fungal pathogen responsible for nosocomial outbreaks worldwide. In addition to antifungal resistance, its ability to persist in the hospital environment and tolerate commonly used biocides presents a critical challenge for infection control. However, the relationship between biocide tolerance, antifungal resistance, and virulence traits in C. auris remains poorly understood.
methodsIn this study, 47 C. auris Clade 1 isolates were evaluated using phenotypic and genotypic methods. ITS region sequencing was performed using Oxford Nanopore technology. Susceptibility testing was conducted for seven antifungal agents and four biocides using the CLSI reference microdilution method. Virulence factors including biofilm formation, secreted aspartyl proteinase, esterase, caseinase, phospholipase, and hemolysis were assessed.
resultsAll isolates were identified as Clade 1. MIC values for antifungals ranged from 0.015 to 64 µg/mL, and for biocides from 0.0078 to 128 mg/L. Fluconazole resistance was found in 31% of isolates, while amphotericin B resistance was 4%; no echinocandin resistance was observed. Biofilm and SAP activity were detected in all isolates; esterase was positive in 87%, and caseinase in 4%. Statistically significant correlations were observed between amphotericin B and isavuconazole MICs (ρ = 0.32, p = 0.028), amphotericin B and triclosan MICs (ρ = 0.35, p = 0.018), and amphotericin B MICs and caseinase activity (ρ = 0.31, p = 0.035). These findings suggest potential phenotypic links between antifungal resistance and specific virulence traits.
conclusionsThis is the first study from Türkiye to evaluate the antifungal and biocide susceptibility alongside virulence characteristics of Clade 1 C. auris. While statistically significant associations were observed, we acknowledge that resistance mechanisms and pathogenicity pathways are distinct. Therefore, these correlations should be interpreted cautiously and warrant further investigation at the molecular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.